BickerstaffLKHollierLHVan PeenenHJ, et al. Abdominal aortic aneurysms: the changing natural history. J Vasc Surg. 1984;1:6–12.
2.
BickerstaffLKPairoleroPCHollierLH, et al. Thoracic aortic aneurysms: a population-based study. Surgery. 1982;92:1103–1108.
3.
AnidjarSKiefferE.Pathogenesis of acquired aneurysms of the abdominal aorta. Ann Vasc Surg. 1992;6:298–305.
4.
MeszarosIMoroczJSzlaviJ, et al. Epidemiology and clinicopathology of aortic dissection. Chest. 2000;117:1271–1278.
5.
PowellJTGreenhalghRM.Clinical practice. Small abdominal aortic aneurysms. N Engl J Med. 2003;348:1895–1901.
6.
CrawfordESCohenES.Aortic aneurysm: a multifocal disease. Presidential address. Arch Surg. 1982;117:1393–1400.
7.
PresslerVMcNamaraJJ.Aneurysm of the thoracic aorta. Review of 260 cases. J Thorac Cardiovasc Surg. 1985;89:50–54.
8.
BrownLCPowellJT.Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg. 1999;230:289–297.
9.
ErnstEReschKL.Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Int Med. 1993;118:956–963.
10.
HovsepianDMZiporinSJSakuraiMK, et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol. 2000;11:1345–1352.
11.
SuzukiTKatohHWatanabeM, et al. Novel biochemical diagnostic method for aortic dissection. Results of a prospective study using an immunoassay of smooth muscle myosin heavy chain. Circulation. 1996;93:1244–1249.
12.
DomanovitsHSchillingerMMullnerM, et al. Acute phase reactants in patients with abdominal aortic aneurysm. Atherosclerosis. 2002;163:297–302.
13.
SchillingerMDomanovitsHBayeganK, et al. C-reactive protein and mortality in patients with acute aortic disease. Intensive Care Med. 2002;28:740–745.
14.
VainasTLubbersTStassenFR, et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation. 2003;107:1103–1105.
15.
KoneckyNMalinowMRTunickPA, et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J. 1997;135:534–540.
16.
TribouilloyCMPeltierMIannetta PeltierMC, et al. Plasma homocysteine and severity of thoracic aortic atherosclerosis. Chest. 2000;118:1685–1689.
17.
SchillingerMDomanovitsHIgnatescuM, et al. Lipoprotein (a) in patients with aortic aneurysmal disease. J Vasc Surg. 2002;36:25–30.
18.
BownMJBurtonPRHorsburghT, et al. The role of cytokine gene polymorphisms in the pathogenesis of abdominal aortic aneurysms: a case-control study. J Vasc Surg. 2003;37:999–1005.
19.
JuvonenJSurcelHMSattaJ, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997;17:2843–2847.
20.
GeorgiadisGSAntoniouGAArgyriouC, et al. Correlation of baseline plasma and inguinal connective tissue metalloproteinases and their inhibitors with late high-pressure endoleak after endovascular aneurysm repair: long-term results. J Endovasc Ther. 2019;26(6):826–835.
21.
GonzálezAASeguraAMHoribaK, et al. Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study. Hum Pathol. 2002;33:1158–1164.
22.
McDonnellSMorganMLynchC.Role of matrix metalloproteinases in normal and disease processes. Biochem Soc Trans. 1999;27:734–740.
23.
MurphyGStantonHCowellS, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS. 1999;107:38–44.
24.
MurphyGKnäuperVCowellS, et al. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci. 1999;878:25–39.
25.
KnoxJBSukhovaGKWhittemoreAD, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 1997;95:205–212.
26.
NewmanKMOgataYMalonAM, et al. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb. 1994;14:1315–1320.
27.
AnnabiBShédidDGhosnP, et al. Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J Vasc Surg. 2002;35:539–546.
28.
FerransVJ.New insights into the world of matrix metalloproteinases. Circulation. 2002;105:405–407.
29.
CarrellTWBurnandKGWellsGM, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation. 2002;105:477–482.
30.
YoonSTrompGVongpunsawadS, et al. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun. 1999;265:563–568.
31.
MedleyTLKingwellBAGatzkaCD, et al. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res. 2003;92:1254–1261.
32.
SangiorgiGD’AverioRMaurielloA, et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation. 1999;104:I288–I295.
33.
HellenthalFATen BoschJAPulinxB, et al. Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg. 2012;43:171–172.
34.
LorelliDRJean-ClaudeJMFoxCJ, et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. J Vasc Surg. 2002;35:916–922.
35.
Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet. 1998;352:1649–1655.
36.
CollinJAraujoLWaltonJ.How fast do very small abdominal aortic aneurysms grow?Eur J Vasc Surg. 1989;3:15–17.
37.
KatzDALittenbergBCronenwettJL.Management of small abdominal aortic aneurysms. Early surgery vs watchful waiting. JAMA. 1992;268:2678–2686.
38.
SansMMoragasA.Mathematical morphologic analysis of the aortic medial structure. Biomechanical implications. Anal Quant Cytol Histol. 1993;15:93–100.
39.
GhorpadeABaxterBT.Biochemistry and molecular regulation of matrix macromolecules in abdominal aortic aneurysms. Ann N Y Acad Sci. 1996;800:138–150.
40.
NakamuraMTachiedaRNiinumaH, et al. Circulating biochemical marker levels of collagen metabolism are abnormal in patients with abdominal aortic aneurysm. Angiology. 2000;51:385–392.
41.
SattaJJuvonenTHaukipuroK, et al. Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples. J Vasc Surg. 1995;22:155–160.
42.
BaxterBTDavisVAMinionDJ, et al. Abdominal aortic aneurysms are associated with altered matrix proteins of the non-aneurysmal aortic segments. J Vasc Surg. 1994;19:797–803.
43.
WilsonKALindholtJSHoskinsPR, et al. The relationship between abdominal aortic aneurysm distensibility and serum markers of elastin and collagen metabolism. Eur J Vasc Endovasc Surg. 2001;21:175–178.
44.
WilsonKBradburyAWhymanM, et al. Relationship between abdominal aortic aneurysm wall compliance and clinical outcome: a preliminary analysis. Eur J Vasc Endovasc Surg. 1998;15:472–477.
45.
LindholtJSHeickendorffLHennebergEW, et al. Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 1997;14:12–16.
46.
LindholtJSHeickendorffLVammenS, et al. Five-year results of elastin and collagen markers as predictive tools in the management of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2001;21:235–240.
47.
ShinoharaTSuzukiKOkadaM, et al. Soluble elastin fragments in serum are elevated in acute aortic dissection. Arterioscler Thromb Vasc Biol. 2003;23:1839–1844.
48.
GoldhaberSZSimonsGRElliottCG, et al. Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA. 1993;270:2819–2822.
49.
BickRL.Disseminated intravascular coagulation. Objective criteria for diagnosis and management. Med Clin North Am. 1994;78:511–543.
50.
CostantiniVZacharskiLR.Fibrin and cancer. Thromb Haemost. 1993;69:406–414.
51.
SerinoFAbeniDGalvagniE, et al. Noninvasive diagnosis of incomplete endovascular aneurysm repair: D-dimer assay to detect type I endoleaks and nonshrinking aneurysms. J Endovasc Ther. 2002;9:90–97.
LindholtJSJorgensenBShiGP, et al. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003;25:546–551.
54.
TribouilloyCPeltierMColasL, et al. Fibrinogen is an independent marker for thoracic aortic atherosclerosis. Am J Cardiol. 1998;81:321–326.
55.
KoenigWHombachVErnstE, et al. Plasma viscosity as a cardiovascular risk factor [letter]. Circulation. 1992;86:1045.
56.
AdamDJHaggartPCLudlamCA, et al. Hemostatic markers before operation in patients with acutely symptomatic nonruptured and ruptured infrarenal abdominal aortic aneurysm. J Vasc Surg. 2002;35:661–665.
57.
AdamDJLudlamCARuckleyCV, et al. Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms. J Vasc Surg. 1999;30:641–650.
58.
FilepJGBodolayESipkaS, et al. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation. 1995;92:2969–2974.
59.
TreskaVWenhamPWValentaJ, et al. Plasma endothelin levels in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 1999;17:424–428.
60.
TateishiJWakuSMasutaniM, et al. Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease. Am Heart J. 2002;143:272–276.
61.
JainKK.Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn. 2003;3:153–161.
